ATE218344T1 - Ranolazin und verwandte piperazine zur behandlung von schockzuständen - Google Patents

Ranolazin und verwandte piperazine zur behandlung von schockzuständen

Info

Publication number
ATE218344T1
ATE218344T1 AT95119463T AT95119463T ATE218344T1 AT E218344 T1 ATE218344 T1 AT E218344T1 AT 95119463 T AT95119463 T AT 95119463T AT 95119463 T AT95119463 T AT 95119463T AT E218344 T1 ATE218344 T1 AT E218344T1
Authority
AT
Austria
Prior art keywords
treatment
ranolazine
piperazines
shock conditions
conditions
Prior art date
Application number
AT95119463T
Other languages
English (en)
Inventor
Robert J Dow
Pierre Ferrandon
Original Assignee
Syntex Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Syntex Llc filed Critical Syntex Llc
Application granted granted Critical
Publication of ATE218344T1 publication Critical patent/ATE218344T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A61K38/166—Streptokinase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/168—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/49—Urokinase; Tissue plasminogen activator
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Botany (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Treatments For Attaching Organic Compounds To Fibrous Goods (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Treatment Of Fiber Materials (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
AT95119463T 1989-06-23 1990-06-21 Ranolazin und verwandte piperazine zur behandlung von schockzuständen ATE218344T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US37043589A 1989-06-23 1989-06-23

Publications (1)

Publication Number Publication Date
ATE218344T1 true ATE218344T1 (de) 2002-06-15

Family

ID=23459660

Family Applications (3)

Application Number Title Priority Date Filing Date
AT95119463T ATE218344T1 (de) 1989-06-23 1990-06-21 Ranolazin und verwandte piperazine zur behandlung von schockzuständen
AT90111787T ATE142497T1 (de) 1989-06-23 1990-06-21 Ranolazin und verwandte piperazine zur behandlung von geweben, von physischen oder chemischen schäden betroffen
AT95119452T ATE223218T1 (de) 1989-06-23 1990-06-21 Ranolazin und verwandte piperazine zum schutz der skelettmuskulatur

Family Applications After (2)

Application Number Title Priority Date Filing Date
AT90111787T ATE142497T1 (de) 1989-06-23 1990-06-21 Ranolazin und verwandte piperazine zur behandlung von geweben, von physischen oder chemischen schäden betroffen
AT95119452T ATE223218T1 (de) 1989-06-23 1990-06-21 Ranolazin und verwandte piperazine zum schutz der skelettmuskulatur

Country Status (13)

Country Link
US (2) US5506229A (de)
EP (3) EP0714660B1 (de)
JP (1) JP3232085B2 (de)
AT (3) ATE218344T1 (de)
AU (1) AU633589B2 (de)
CA (1) CA2019580C (de)
DE (3) DE69034000T2 (de)
DK (3) DK0719558T3 (de)
ES (3) ES2177601T3 (de)
GR (1) GR3020976T3 (de)
IE (1) IE80710B1 (de)
NZ (2) NZ234184A (de)
ZA (1) ZA904842B (de)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69833665T2 (de) 1997-08-08 2006-11-09 Duke University Zusammensetzungen zur vereinfachung von chirurgischen verfahren
US6711436B1 (en) 1997-08-08 2004-03-23 Duke University Compositions, apparatus and methods for facilitating surgical procedures
US6303607B1 (en) * 1998-09-10 2001-10-16 Cv Therapeutics, Inc. Method for administering a sustained release ranolanolazine formulation
US6479496B1 (en) * 1998-09-10 2002-11-12 Cv Therapeutics, Inc. Methods for treating angina with ranolazine
HK1048250A1 (zh) 2000-02-18 2003-03-28 Cv Therapeutics, Inc. 在治疗充血性心力衰竭中使用的部分脂肪酸氧化抑制剂
US6552023B2 (en) 2000-02-22 2003-04-22 Cv Therapeutics, Inc. Aralkyl substituted piperazine compounds
US6677336B2 (en) 2000-02-22 2004-01-13 Cv Therapeutics, Inc. Substituted piperazine compounds
US6677343B2 (en) 2000-02-22 2004-01-13 Cv Therapeutics, Inc. Substituted piperazine compounds
CA2657986A1 (en) * 2000-02-22 2001-08-30 Cv Therapeutics, Inc. Substituted piperazine compounds
US6638970B2 (en) 2000-02-22 2003-10-28 Cv Therapeutics, Inc. Substituted alkylene diamine compounds
US6451798B2 (en) 2000-02-22 2002-09-17 Cv Therapeutics, Inc. Substituted alkyl piperazine derivatives
CA2420182A1 (en) * 2000-08-25 2002-03-07 Organ Recovery Systems, Inc. Methods of thrombolytic organ treatment and repair
US6573264B1 (en) * 2000-10-23 2003-06-03 Cv Therapeutics, Inc. Heteroaryl alkyl piperazine derivatives
GB0028414D0 (en) 2000-11-22 2001-01-03 Univ Leeds Flush preservation solution
US20030220344A1 (en) * 2002-04-04 2003-11-27 Luiz Belardinelli Method of treating arrhythmias
US8822473B2 (en) * 2002-05-21 2014-09-02 Gilead Sciences, Inc. Method of treating diabetes
CA2486712C (en) * 2002-05-21 2012-01-03 Cv Therapeutics, Inc. Method of treating diabetes
JP2006510670A (ja) 2002-12-05 2006-03-30 シーブイ・セラピューティクス・インコーポレイテッド 置換ヘテロ環化合物
JP2006514066A (ja) 2003-01-03 2006-04-27 シーブイ・セラピューティクス・インコーポレイテッド 置換ヘテロ環化合物
AU2004209522A1 (en) 2003-01-17 2004-08-19 Gilead Palo Alto, Inc. Substituted heterocyclic compounds useful in the treatment of cardiovascular diseases
KR20060065586A (ko) 2003-06-23 2006-06-14 씨브이 쎄러퓨틱스, 인코포레이티드 지방산 산화 저해제로서의, 피페라진 및 피페리딘의 우레아유도체
WO2005061470A1 (en) 2003-12-18 2005-07-07 Cv Therapeutics, Inc. 1-akan-2-ol substituted piperazine and piperidine compounds
EP1789407A2 (de) * 2004-09-08 2007-05-30 Cv Therapeutics, Inc. Substituierte piperazinverbindungen und ihre verwendung als fettsäureoxidationsinhibitoren
WO2006053161A1 (en) * 2004-11-09 2006-05-18 Cv Therapeutics, Inc. Use ranolazine in combination with at least one remodeling agent for reversing left ventricular remodeling in the treatment of heart failure
WO2006074398A2 (en) * 2005-01-06 2006-07-13 Cv Therapeutics, Inc. Sustained release pharmaceutical formulations comprising ranolazine
US20060205727A1 (en) * 2005-03-11 2006-09-14 Wayne Kaesemeyer Combination therapy for endothelial dysfunction, angina and diabetes
US20090312340A1 (en) * 2007-02-13 2009-12-17 Whedy Wang Use of ranolazine for the treatment of cardiovascular diseases
US20090111826A1 (en) * 2007-02-13 2009-04-30 Louis Lange Use of ranolazine for the treatment of cardiovascular diseases
EP2117508A1 (de) 2007-02-13 2009-11-18 CV Therapeutics Inc. Intravenöse lösungen mit ranolazin
JP2010518171A (ja) * 2007-02-13 2010-05-27 ギリアード・パロ・アルト・インコーポレイテッド 非冠微小血管疾患の処置のためのラノラジンの使用
US20080248112A1 (en) * 2007-02-13 2008-10-09 Brent Blackburn Use of ranolazine for the treatment of coronary microvascular diseases
US20080233191A1 (en) * 2007-03-22 2008-09-25 Brent Blackburn Use of ranolazine for elevated brain-type natriuretic peptide
RU2442585C2 (ru) * 2007-05-31 2012-02-20 Си Ви Терапьютикс, Инк. Способ лечения диабета
WO2008150565A2 (en) * 2007-05-31 2008-12-11 Cv Therapeutics, Inc. Ranolazine for elevated brain-type natriuretic peptide
CA2713521A1 (en) * 2008-02-06 2009-08-13 Gilead Palo Alto, Inc. Use of ranolazine for treating pain
US20090247535A1 (en) * 2008-03-26 2009-10-01 Duke University Use of ranolazine for non-cardiovascular disorders
US20100292217A1 (en) * 2009-05-14 2010-11-18 Gilead Palo Alto, Inc. Ranolazine for the treatment of cns disorders
US8901128B2 (en) 2009-05-28 2014-12-02 Lupin Limited Pharmaceutical compositions of ranolazine
EP2453893A4 (de) * 2009-07-09 2012-06-20 Ozteo Pty Ltd Behandlung nicht neuronaler und nicht myokardialer zell-, gewebe- und organschäden und der damit verbundenen schmerzen durch dauerhafte natriumkanalblocker
AU2015200961B2 (en) * 2009-07-09 2017-02-16 Ozteo Pty Ltd Treatment of Non-Neuronal and Non-Cardiac Cell, Tissue and Organ Damage and Associated Pain with Persistent Sodium Current Blockers
US20120177729A1 (en) 2009-09-25 2012-07-12 Lupin Limited Sustained release composition of ranolazine
TWI508726B (zh) 2009-12-21 2015-11-21 Gilead Sciences Inc 治療心房纖維性顫動之方法
WO2012170676A1 (en) * 2011-06-08 2012-12-13 Sti Pharma, Llc Controlled absorption water-soluble pharmaceutically active organic compound formulation for once-daily administration
KR101476379B1 (ko) * 2011-11-30 2014-12-29 한국과학기술연구원 페녹시프로판올 유도체 및 이를 함유하는 약학적 조성물
KR101331186B1 (ko) * 2013-08-05 2013-11-22 한국과학기술연구원 페녹시프로판올 유도체 및 이를 함유하는 약학적 조성물
WO2021252951A1 (en) 2020-06-12 2021-12-16 Vanderbilt University Methods of treatment for gastrointestinal motility disorders
WO2023045740A1 (zh) * 2021-09-27 2023-03-30 天士力医药集团股份有限公司 一种治疗心肌缺血的药物组合物及其制备方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4567264A (en) * 1983-05-18 1986-01-28 Syntex (U.S.A.) Inc. Cardioselective aryloxy- and arylthio- hydroxypropylene-piperazinyl acetanilides which affect calcium entry

Also Published As

Publication number Publication date
DE69033967D1 (de) 2002-07-11
DE69034000T2 (de) 2003-06-05
JP3232085B2 (ja) 2001-11-26
ES2091211T3 (es) 1996-11-01
DK0719558T3 (da) 2002-10-07
ES2182863T3 (es) 2003-03-16
NZ234184A (en) 1997-01-29
AU5761890A (en) 1991-01-03
EP0407780A3 (en) 1992-01-02
IE80710B1 (en) 1998-12-16
DK0714660T3 (da) 2002-10-07
DK0407780T3 (da) 1996-09-30
US5506229A (en) 1996-04-09
EP0714660A1 (de) 1996-06-05
EP0719558B1 (de) 2002-06-05
JPH0348672A (ja) 1991-03-01
EP0407780B1 (de) 1996-09-11
GR3020976T3 (en) 1996-12-31
CA2019580C (en) 2007-03-27
ATE223218T1 (de) 2002-09-15
DE69034000D1 (de) 2002-10-10
EP0407780A2 (de) 1991-01-16
DE69033967T2 (de) 2002-12-19
CA2019580A1 (en) 1990-12-23
IE902250A1 (en) 1991-01-16
NZ247044A (en) 1997-04-24
DE69028457D1 (de) 1996-10-17
ATE142497T1 (de) 1996-09-15
EP0719558A1 (de) 1996-07-03
US5906988A (en) 1999-05-25
ZA904842B (en) 1992-02-26
DE69028457T2 (de) 1997-02-20
ES2177601T3 (es) 2002-12-16
AU633589B2 (en) 1993-02-04
IE902250L (en) 1990-12-23
EP0714660B1 (de) 2002-09-04

Similar Documents

Publication Publication Date Title
ATE218344T1 (de) Ranolazin und verwandte piperazine zur behandlung von schockzuständen
DE69921156D1 (de) Verwendung von 5ht-6 antagonisten zur behandlung adhd
DE58902313D1 (de) Verfahren zur sterilisation von blut, plasma, blut- und plasmaderivaten, zellsuspensionen oder dgl.
DE69528475D1 (de) Verwendung von serotonin-antagonisten (5ht3) zur behandlung von fibromyalgie
DE68929554D1 (de) Piperazinyl-substituierte Phenylpyrimidinderivative zur Behandlung oder Vorbeugung von ZNS Erkrankungen
DE3683318D1 (de) Verwendung von alfuzosin zur behandlung von erkrankungen der harnwege.
DE58900119D1 (de) Chirurgisches instrument zum einsetzen von hueftpfannen-prothesen.
DE3788057D1 (de) Verwendung von heterocyclischen Verbindungen zur Behandlung von Depressionen.
ATE130589T1 (de) Verwendung von wässrigen kationischen kunststoffdispersionen zum imprägnieren und grundieren von saugfähigen substraten.
DE3851584D1 (de) Gegen Allergie wirkende Benzothiophene und neue und andere ausgewählte Benzothiophene, beide mit Wirkung zur Behandlung von akuten Atmungsangstanzeichen.
DE3681642D1 (de) Benzopyran-verbindungen zur behandlung von inkontinenz.
DE59003534D1 (de) Verfahren zur Herstellung von Triethylendiamin und Piperazin.
ATE179594T1 (de) Verwendung von ethisterone zur topischen behandlung von akne oder androgenetischer alopezie
ATE148109T1 (de) Hiv-proteaseinhibitoren und ihre verwendung zur behandlung von aids
DE69827387D1 (de) Verwendung von pramipexol zur behandlung von restless-legs-syndrom
DE68907569D1 (de) Mittel zur behandlung oder vorbeugung von aids.
ATE25969T1 (de) 1,7-diphenyl-3-methylaza-7-cyan-8-methyl-nonan zur verwendung bei der bekaempfung von krankheiten.
DE3875016D1 (de) Therapeutikum zur behandlung von aids.
DE3686688D1 (de) Verwendung von sulfanilamido quinoxalinen zur behandlung von neoplastischen krankheiten.
DE3486005D1 (de) Anwendung von carbamate oder thiocarbamat-derivaten zur behandlung von fungus-infektionen.
ATE136463T1 (de) Verwendung von 1,2,3,4-tetrahydroacridinen zur behandlung von aids, sowie verbindungen
DE68916814D1 (de) Mittel zur behandlung von pediculosis capitis.
DE69711422D1 (de) Verwendung von (r)-verapamil als medizin zur behandlung von angina
DE69001988D1 (de) Behandlung des schocks mit cyclodextrin und dessen derivaten.
DE69022027D1 (de) 2-Alkyl-3-benzoylbenzofurane zur Behandlung von Herzarrhythmia.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
EELA Cancelled due to lapse of time